BERLIN — Germany gave the green light for human trials of potential coronavirus vaccines developed by German biotech company BioNTech. Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there.
The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people, with more subjects, including some at higher risk from the disease, to be included in a second stage, German vaccines regulator the Paul Ehrlich Institute.
Two different experimental coronavirus vaccines were approved for human tests by China last week. A unit of Sinovac Biotech and the Wuhan Institute of Biological Products are developing these compounds. In March, China gave the green-light for another clinical trial for a vaccine candidate developed by the Academy of Military Medical Sciences and biotech firm CanSino Bio.
Source: The New York Times
FINANCED BY
This project was funded in part through a U.S. Embassy grant. The opinions, findings, and conclusions or recommendations expressed herein are those of the implementers/authors and do not necessarily reflect those of the U.S. Government.
PARTNERS
